2. Academic Validation
  3. Using FDA-approved drugs as off-label fluorescent dyes for optical biopsies: from in silico design to ex vivo proof-of-concept

Using FDA-approved drugs as off-label fluorescent dyes for optical biopsies: from in silico design to ex vivo proof-of-concept

  • Methods Appl Fluoresc. 2021 Jun 4;9(3). doi: 10.1088/2050-6120/ac0619.
Michael C Larson 1,  Arthur F Gmitro 1 2 3,  Urs Utzinger 2 3 4 5 6,  Andrew R Rouse 1 3 7,  Gregory J Woodhead 1,  Quinlan Carlson 8,  Charles T Hennemeyer 1,  Jennifer K Barton 1 2 3 4 5
Affiliations

Affiliations

  • 1 Medical Imaging, University of Arizona/Banner-University Medical Center, United States of America.
  • 2 Biomedical Engineering Department, University of Arizona, United States of America.
  • 3 College of Optical Sciences, University of Arizona, United States of America.
  • 4 Electrical and Computer Engineering Department, University of Arizona, United States of America.
  • 5 BIO5 Institute, University of Arizona, United States of America.
  • 6 Obstetrics & Gynecology, University of Arizona/Banner-University Medical Center, United States of America.
  • 7 Research, Innovation and Impact, University of Arizona, United States of America.
  • 8 Post-Sophomore Fellowship in Pathology, College of Medicine, University of Arizona, United States of America.
PMID: 34044380 DOI: 10.1088/2050-6120/ac0619
Abstract

Optical biopsies bring the microscope to the patient rather than the tissue to the microscope, and may complement or replace the tissue-harvesting component of the traditional biopsy process with its associated risks. In general, optical biopsies are limited by the lack of endogenous tissue contrast and the small number of clinically approvedin vivodyes. This study tests multiple FDA-approved drugs that have structural similarity to research dyes as off-labelin situfluorescent alternatives to standardex vivohematoxylin & eosin tissue stain. Numerous drug-dye combinations shown here may facilitate relatively safe and fastin situor possiblyin vivostaining of tissue, enabling real-time optical biopsies and other advanced microscopy technologies, which have implications for the speed and performance of tissue- and cellular-level diagnostics.

Keywords

drug repurposing; fluorescence; fluorescence histopathology; fluorescent dyes; intravital microscopy; optical biopsy; optical imaging.

Figures
Products